GENETHON - France 

Ranking results:

Past rankings:

2020
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:> 1000
Total Number of Projects:> 1000
2019
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:> 1000
Total Number of Projects:> 1000
2018
Criterium:Position:
Overall Score:500-600
Total Project Funding per Partner:300-400
Total Number of Projects:> 1000
Networking Rank (Reputation):400-500
2016
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
2015
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
2012
Criterium:Position:
Overall Score:900-1000
Total Project Funding per Partner:> 1000
Total Number of Projects:70
Total Project Funding:> 1000
Networking Rank (Reputation):> 1000
Networking Rank (Reputation):> 1000
Partner Constancy:46
Project Leadership Index:75
Diversity Index:60
2011
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:300-400
Total Number of Projects:> 1000
Total Project Funding:> 1000
Networking Rank (Reputation):> 1000
Partner Constancy:> 1000
Project Leadership Index:> 1000
Diversity Index:> 1000
2009
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
2008
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:> 1000
Total Number of Projects:> 1000
Total Project Funding:> 1000
Networking Rank (Reputation):> 1000
Partner Constancy:> 1000
Project Leadership Index:> 1000
Diversity Index:> 1000
2007
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:400-500
Total Number of Projects:900-1000
Total Project Funding:400-500
Networking Rank (Reputation):> 1000
Partner Constancy:> 1000
Project Leadership Index:> 1000
Diversity Index:> 1000

Ranking timeline:

Project Participation Performance(2010-01-01 - 2025-12-31 ):

Total Project Funding:

Total funding allocated to projects this organisation participated or coordinated

Funding per Partner:

Since 2014 individual funding per partner. If data is not available at CORDIS: total funding / No of participants.

Projects:

Leadership:

Total number of projects: 15
As coordinator: 2
As participant: 10
Sole participant: 3
Coordinator / Participant Ratio: 0.2*

*Ratio includes only projects with > 2 partners

Summary:

Total project funding [€]:Projects [No]:
Year:coordinator*participant*per partner  as coordinatoras participant
2022 0 4.000.000 591.000 1
2020 0 11.773.000 311.250 1
2019 173.076 0 173.076 1
2018 6.249.104 5.998.516 3.829.548 1 1
2017 185.076 0 185.076 1
2016 173.076 14.383.251 2.540.739 1 3
2015 0 5.980.435 0 1
2013 0 5.380.170 630.919 1
2012 5.999.607 0 545.419 1
2011 0 7.171.654 2.541.158 2
*n.b.: These numbers represent the total amount of funds allocated to projects this institution has participated in, not the funding allocated to this institution

Networking:

Partners:

Institution:Projects [No]:
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS4
GENOSAFE SAS4
MEDIZINISCHE HOCHSCHULE HANNOVER4
UNIVERSITY COLLEGE LONDON4
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE3
ASPHALION SL2
DEUTSCHES KREBSFORSCHUNGSZENTRUM2
EURICE EUROPEAN RESEARCH AND PROJECT OFFICE2
EUROPAEISCHES INSTITUT FUER FORSCHUNG UND ENTWICKLUNG VON TRANSPLANTATIONSSTRATEGIEN2
FONDAZIONE TELETHON2
GATC BIOTECH2
THE UNIVERSITY OF LIVERPOOL2
UNIVERSITa DEGLI STUDI DI NAPOLI 'FEDERICO II'2
UNIVERSITAETSKLINIKUM HEIDELBERG2
UNIVERSITAT AUTONOMA DE BARCELONA2
ACADEMIC MEDICAL CENTRE AMSTERDAM1
ACADEMISCH ZIEKENHUIS LEIDEN1
ASSOCIATION FRANCAISE DE CRIGLER NAJJAR1
ASTELLAS PHARMA EUROPE BV1
AZIENDA OSPEDALIERA PAPA GIOVANNI XXIII1
BAYER1
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS1
CENTRO DE INVESTIGACIONES ENERGETICAS MEDIOAMBIENTALES Y TECNOLOGICAS1
CENTRO DE NEUROCIENCIAS E BIOLOGIACELULAR ASSOCIACAO1
CHRISTOS PAPADOPOULOS & SIA OE1
CINFERENCE UG1
COMMISSARIAT A L'ENERGIE ATOMIQUE1
DEBRA EUROPE1
DLD GESELLSCHAFT FUR DIAGNOSTIKA UND MEDIZINISCHE GERATE MBH1
ENVIGO CRS LIMITED1
EUROPEAN MOLECULAR BIOLOGY LABORATORY1
FINOVATIS1
FONDAZIONE PER LA RICERCA BIOMEDICA AVANZATA ONLUS1
FUNDACION PARA LA INVESTIGACION BIOMEDICA HOSPITAL INFANTIL UNIVERSITARIO NINO JESUS1
FUNDACION PARA LA INVESTIGACION MEDICA APLICADA1
GENEWERK1
GEORG SPEYER HAUS CHEMOTHERAPEUTISCHES FORSCHUNGSINSTITUT1
GREAT ORMOND STREET HOSPITAL FOR CHILDREN NHS FOUNDATION TRUST1
HET ROTTERDAMS OOGHEELKUNDIG INSTITUUT BV1
IMMUNDIAGNOSTIK1
INNOVACION DESARROLLO Y TRANSFERENCIA DE TECNOLOGIA1
INNOVAVECTOR1
INSERM TRANSFERT1
INSTITUT CATALA DE LA SALUT1
INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE1
INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLOGICA1
INSTITUTO INVESTIGACION SANITARIA FUNDACION JIMENEZ DIAZ1
INTERNATIONAL PATIENT ORGANISATION FOR PRIMARY IMMUNODEFICIENCIES1
JANSSEN PHARMACEUTICA NV1
KING'S COLLEGE LONDON1
KLINIKUM DER JOHANN WOLFGANG GOETHE UNIVERSITAET1
KNIGHT SCIENTIFIC LIMITED1
LONZA1
LUND UNIVERSITY1
LYSOGENE1
MC TOXICOLOGY CONSULTING1
MILTENYI BIOTEC1
MIMETAS BV1
MYOMEDIX1
NEXT GENERATION DIAGNOSTIC1
NOVARTIS PHARMA1
NOVO NORDISK1
OSPEDALE SAN RAFFAELE1
PANEPISTIMIO THESSALIAS1
PFIZER LIMITED1
PHARMACOIDEA FEJLESZTO ES SZOLGALTATO KFT1
REITHERA1
RUPRECHT KARLS UNIVERSITAET HEIDELBERG1
SANOFIAVENTIS1
SERVICIO MADRILENO DE SALUD1
SORBONNE UNIVERSITE1
SPARK THERAPEUTICS INC1
STELLENBOSCH UNIVERSITY1
STICHTING OOGZIEKENHUIS ROTTERDAM1
STICHTING VU1
STICHTING VUMC1
SYNVACCINE1
TAKEDA PHARMACEUTICALS INTERNATIONAL1
TAKIS1
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD1
THE ROSALIND FRANKLIN INSTITUTE1
THE UNIVERSITY OF SHEFFIELD1
TZARTOS DIAGNOSIS & RESEARCH IN NEUROIMMUNOLOGY MEDICAL LIMITED LIABILITY COMPANY1
UNIVERSIDAD CARLOS III DE MADRID1
UNIVERSITA DEGLI STUDI DELLA CAMPANIA LUIGI VANVITELLI1
UNIVERSITA DEGLI STUDI DI MILANO BICOCCA1
UNIVERSITA DEGLI STUDI DI MODENA E REGGIO EMILIA1
UNIVERSITA DEGLI STUDI DI TRENTO1
UNIVERSITAET ZUERICH1
UNIVERSITAETSKLINIKUM FREIBURG1
UNIVERSITAT KONSTANZ1
UNIVERSITE DE PARIS VII DENIS DIDEROT1
UNIVERSITE PIERRE ET MARIE CURIE PARIS 61
UNIVERSITY OF ARIZONA COLLEGE OF MEDICINEPHOENIX1
UNIVERSITY OF CALIFORNIA SAN FRANCISCO SCHOOL OF MEDICINE1
UNIVERSITY OF CAMBRIDGE1
UNIVERSITY OF EASTERN FINLAND1
UNIVERSITY OF FLORIDA1
UNIVERSITY OF LEICESTER1
UNIVERSITY OF ST MARK & ST JOHN1

Constancy:

Total number of partners: 127
Partner loyalty:
Frequent Partner: (> 2 projects): 19
Rare Partner: 108
Frequent / Rare Partner Ratio: 0.18

Project overview:

Start dateProjectacronymrolefundingpartners
2022-10-01Next-generation AAV vectors for liver-directed gene therapy AAVolutionparticipant4.000.0009
2020-11-01Accelerating Research & Development for Advanced Therapies ARDATparticipant11.773.00034
2019-01-01Targeting mitochondrial defects and oxidative stress in Pompe Disease: from pathogenesis to therapy MITOPOMPEcoordinator173.0761
2018-01-01Adeno-Associated Virus Vector-Mediated Liver Gene Therapy for Crigler-Najjar Syndrome CureCNcoordinator6.249.10411
2018-01-01Clinical trial of gene therapy with dual AAV vectors for retinitis pigmentosa in patients with Usher syndrome type IB UshTherparticipant5.998.5169
2017-03-01Correction of duplications in the DMD gene by a CRISPR/Cas9 approach DMD2CUREcoordinator185.0761
2016-03-01Muscle Stress Relief: An integrated research program linking together basic research on secondary myopathies in stress states to innovative translation in applied myology. Muscle stress reliefparticipant1.458.00021
2016-01-01Development of an innovative gene therapy platform to cure rare hereditary muscle disorders MYOCUREparticipant5.998.9389
2016-01-01DevelopIng Genetic medicines for Severe Combined Immunodeficiency (SCID) SCIDNETparticipant6.926.31312
2016-01-01Genetic correction of glycogen debranching enzyme deficiency in Glycogen Storage disease III: a proof of concept study GLYCODIS3coordinator173.0761
2015-09-01Efficacy and safety of low-dose IL-2 (ld-IL-2) as a Treg enhancer for anti-neuroinflammatory therapy in newly diagnosed Amyotrophic Lateral Sclerosis (ALS) patients MIROCALSparticipant5.980.43512
2013-01-01Phase I/II Gene Therapy Trial of Fanconi anemia patients with a new Orphan Drug consisting of a lentiviral vector carrying the FANCA gene: A Coordinated International Action EUROFANCOLENparticipant5.380.17011
2012-12-01Gene Therapy for X-linked Chronic Granulomatous Disease (CGD) NET4CGDcoordinator5.999.60711
2011-12-01Gene Therapy for Inherited Skin Adhesion Disorders GT-SKINparticipant2.210.0001
2011-03-01Phase I/II ex vivo gene therapy clinical trial for recessive dystrophic epidermolysis bullosa using skin equivalent grafts genetically corrected with a COL7A1-encoding SIN retroviral vector GENEGRAFTparticipant4.961.65410

Alias institution names:

  • ASSOCIATION GENETHON
  • GENETHON